BSF Enterprise PLC Result of Annual General Meeting
20 March 2024 - 11:56PM
RNS Regulatory News
RNS Number : 6424H
BSF Enterprise PLC
20 March 2024
20 March 2024
BSF Enterprise
PLC
("BSF" or
the "Company")
Result of
Annual General Meeting
BSF Enterprise (LSE: BSFA), (OTCQB:
BSFAF), the Main Market listed biotech company and owner of
pioneering UK-based tissue engineering company 3D Bio-Tissues Ltd
(3DBT) and corneal tissue replacement company Kerato Ltd, is
pleased to announce that at the Company's Annual General Meeting
held earlier today, all resolutions proposed were duly passed by
shareholders by way of a poll, the results of which were as
follows:
Resolution
|
Poll
Results
|
For
|
Against
|
Withheld
|
Discretionary
|
Total
|
1
|
Shares
|
52,426,227
|
-
|
-
|
-
|
52,426,227
|
%
|
100.00%
|
-
|
-
|
-
|
100%
|
2
|
Shares
|
52,421,227
|
5,000
|
-
|
-
|
52,426,227
|
%
|
99.99%
|
0.01%
|
-
|
-
|
100%
|
3
|
Shares
|
52,421,227
|
5,000
|
-
|
-
|
52,426,227
|
%
|
99.99%
|
0.01%
|
-
|
-
|
100%
|
4
|
Shares
|
52,426,227
|
-
|
-
|
-
|
52,426,227
|
%
|
100.00%
|
-
|
|
-
|
100%
|
5
|
Shares
|
46,646,377
|
-
|
5,779,850
|
-
|
52,426,227
|
%
|
88.98%
|
-
|
11.02%
|
-
|
100%
|
6
|
Shares
|
52,426,227
|
-
|
-
|
-
|
52,426,227
|
%
|
100.00%
|
-
|
-
|
-
|
100%
|
7
|
Shares
|
52,402,826
|
23,401
|
-
|
-
|
52,426,227
|
%
|
99.96%
|
0.04%
|
-
|
-
|
100%
|
8
|
Shares
|
52,421,227
|
-
|
5,000
|
-
|
52,426,227
|
%
|
99.99%
|
-
|
0.01%
|
|
100%
|
9
|
Shares
|
52,397,826
|
23,401
|
5,000
|
-
|
52,426,227
|
%
|
99.95%
|
0.04%
|
0.01%
|
-
|
100%
|
About BSF Enterprise PLC:
BSF Enterprise PLC (BSF) is focused
on unlocking the next generation of biotechnological solutions -
using cellbased tissue engineering to help generate cultured meat,
lab-grown leather, as well as human corneas, collagen growth and
skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.
It owns 100% of 3D Bio-Tissues
(3DBT), a tissue engineering with patent-protected IP that is
already producing human corneas for testing to help restore vision
to millions of people. Building on this success, it aims to produce
the UK's first high quality leather from its laboratory in
Newcastle, transforming the leather industry towards an ethical and
sustainable practice.
BSF aims to deliver growth to
shareholders through the continued commercialisation of 3DBT's IP,
which has multiple applications, as well as through M&A. It
aims to develop a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and
license out the IP to manufacturers, wholesalers and distributors
to help manufacture the products at scale.
For further enquiries, please visit
www.bsfenterprise.com or contact:
BSF Enterprise PLC
|
Via SEC Newgate below
|
Geoff Baker - Executive
Director
Che Connon - CEO &
Director
|
|
Shard Capital (Broker)
|
|
Damon Heath
Isabella Pierre
|
0207 186 9000
0207 186 9927
|
SEC Newgate (Financial
Communications)
|
|
Bob Huxford
|
020 3757 6882
|
Elisabeth Cowell
|
BSF@secnewgate.co.uk
|
ISIN of the Ordinary Shares
is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGURVURSVUOUAR
Bsf Enterprise (LSE:BSFA)
Historical Stock Chart
From Nov 2024 to Dec 2024
Bsf Enterprise (LSE:BSFA)
Historical Stock Chart
From Dec 2023 to Dec 2024